Giovanni Marzaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5216151/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening. International Journal of Molecular Sciences, 2022, 23, 6630.	1.8	8
2	Dual Kinase Targeting in Leukemia. Cancers, 2021, 13, 119.	1.7	2
3	Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting. Molecules, 2021, 26, 918.	1.7	8
4	Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment. Journal of Controlled Release, 2021, 340, 318-330.	4.8	8
5	Preliminary evaluation of the production of non-carrier added 111Ag as core of a therapeutic radiopharmaceutical in the framework of ISOLPHARM_Ag experiment. Applied Radiation and Isotopes, 2020, 164, 109258.	0.7	10
6	Toward novel sulphur-containing derivatives of tetraazacyclododecane: synthesis, acid–base properties, spectroscopic characterization, DFT calculations, and cadmium(<scp>ii</scp>) complex formation in aqueous solution. New Journal of Chemistry, 2020, 44, 8337-8350.	1.4	11
7	Surface plasmon resonance based analysis of the binding of LYAR protein to the rs368698783 (G>A) polymorphic Aγ-globin gene sequences mutated in β-thalassemia. Analytical and Bioanalytical Chemistry, 2019, 411, 7699-7707.	1.9	1
8	Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. European Journal of Medicinal Chemistry, 2019, 172, 143-153.	2.6	72
9	Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB). European Journal of Medicinal Chemistry, 2018, 151, 285-293.	2.6	13
10	Corilagin Induces High Levels of Apoptosis in the Temozolomide-Resistant T98G Glioma Cell Line. Oncology Research, 2018, 26, 1307-1315.	0.6	18
11	Early Evaluation of Copper Radioisotope Production at ISOLPHARM. Molecules, 2018, 23, 2437.	1.7	16
12	Targeting DNA Binding for NF-κB as an Anticancer Approach in Hepatocellular Carcinoma. Cells, 2018, 7, 177.	1.8	11
13	Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators. Frontiers in Pharmacology, 2018, 9, 719.	1.6	28
14	Known Triterpenes and their Derivatives as Scaffolds for the Development of New Therapeutic Agents for Cancer. Current Medicinal Chemistry, 2018, 25, 1259-1269.	1.2	30
15	Multicomponent Assembly of the Kinesin Spindle Protein Inhibitor CPUYJ039 and Analogues as Antimitotic Agents. ACS Combinatorial Science, 2017, 19, 153-160.	3.8	5
16	Discovery of ^{wt} RET and ^{V804M} RET Inhibitors: From Hit to Lead. ChemMedChem, 2017, 12, 1390-1398.	1.6	7
17	Differential Effects of Angelicin Analogues on NF- <i>κ</i> B Activity and IL-8 Gene Expression in Cystic Fibrosis IB3-1 Cells. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	16
18	Substituted quinazolinones as kinase inhibitors endowed with anti-fibrotic properties. European Journal of Medicinal Chemistry, 2016, 115, 416-425.	2.6	12

#	Article	IF	CITATIONS
19	Novel benzoquinoline derivatives via unpredicted condensation of ethyl propiolate and naphthylamines: Synthesis and topoisomerase inhibition activity. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4875-4878.	1.0	6
20	Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). Expert Opinion on Investigational Drugs, 2016, 25, 1215-1230.	1.9	24
21	Structural and Functional Insights on an Uncharacterized Aγ-Globin-Gene Polymorphism Present in Four βO-Thalassemia Families with High Fetal Hemoglobin Levels. Molecular Diagnosis and Therapy, 2016, 20, 161-173.	1.6	17
22	Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Scientific Reports, 2015, 5, 16750.	1.6	53
23	Psoralen derivatives as inhibitors of NF- \$\$upkappa hbox {B/DNA}\$\$ κ B/DNA interaction: the critical role of the furan ring. Molecular Diversity, 2015, 19, 551-561.	2.1	6
24	Lejeuneaceae (Marchantiophyta) from a species-rich taphocoenosis in Miocene Mexican amber, with a review of liverworts fossilised in amber. Review of Palaeobotany and Palynology, 2015, 221, 59-70.	0.8	36
25	Photobiological properties of 3-psoralenacetic acids. Photochemical and Photobiological Sciences, 2015, 14, 2074-2086.	1.6	3
26	Pyrroloquinolinone-based dual topoisomerase I/II inhibitor. European Journal of Medicinal Chemistry, 2014, 77, 103-109.	2.6	13
27	Autogrid-based clustering of kinases: selection of representative conformations for docking purposes. Molecular Diversity, 2014, 18, 611-619.	2.1	3
28	Discovery of Biarylaminoquinazolines as Novel Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 4598-4605.	2.9	28
29	Photochemical and photobiological studies on furoquinazolines as new psoralen analogs. Journal of Photochemistry and Photobiology B: Biology, 2014, 138, 43-54.	1.7	9
30	QSAR and 3D-QSAR Models in the Field of Tubulin Inhibitors as Anticancer Agents. Current Topics in Medicinal Chemistry, 2014, 14, 2253-2262.	1.0	7
31	Quinazoline-based multi-tyrosine kinase inhibitors: Synthesis, modeling, antitumor and antiangiogenic properties. European Journal of Medicinal Chemistry, 2013, 67, 373-383.	2.6	59
32	Psoralen Derivatives as Inhibitors of NF-κB/DNA Interaction: Synthesis, Molecular Modeling, 3D-QSAR, and Biological Evaluation. Journal of Medicinal Chemistry, 2013, 56, 1830-1842.	2.9	34
33	The Moss Macromitrium Richardii (Orthotrichaceae) with Sporophyte and Calyptra Enclosed in Hymenaea Resin from the Dominican Republic. Polish Botanical Journal, 2013, 58, 221-230.	0.5	17
34	Quinazoline derivatives as potential anticancer agents: a patent review (2007 – 2010). Expert Opinion on Therapeutic Patents, 2012, 22, 223-252.	2.4	104
35	New Vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential. Investigational New Drugs, 2012, 30, 594-603.	1.2	7
36	Development of a novel furocoumarin derivative inhibiting NF-κB dependent biological functions: Design, synthesis and biological effects. European Journal of Medicinal Chemistry, 2011, 46, 4870-4877.	2.6	38

GIOVANNI MARZARO

#	Article	IF	CITATIONS
37	Benzoquinazoline derivatives as new agents affecting DNA processing. Bioorganic and Medicinal Chemistry, 2011, 19, 1197-1204.	1.4	18
38	The Importance of Descriptorâ€Based Clusterization in QSAR Models Development: Tyrosine Kinases Inhibitors as a Key Study. Molecular Informatics, 2011, 30, 721-732.	1.4	1
39	Psoralenquinones as a Novel Class of Proteasome Inhibitors: Design, Synthesis and Biological Evaluation. ChemMedChem, 2011, 6, 996-1000.	1.6	3
40	Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 2185-2192.	2.6	62
41	A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines. Tetrahedron, 2010, 66, 962-968.	1.0	34
42	Exploring Epidermal Growth Factor Receptor (EGFR) Inhibitor Features: The Role of Fused Dioxygenated Rings on the Quinazoline Scaffold. Journal of Medicinal Chemistry, 2010, 53, 1862-1866.	2.9	51
43	Synthesis and antitumor activity of novel amsacrine analogs: The critical role of the acridine moiety in determining their biological activity. Bioorganic and Medicinal Chemistry, 2009, 17, 523-529.	1.4	56
44	Microwave-promoted mono-N-alkylation of aromatic amines in water: a new efficient and green method for an old and problematic reaction. Green Chemistry, 2009, 11, 774.	4.6	39
45	A microwave improvement in the synthesis of the quinazoline scaffold. Tetrahedron Letters, 2007, 48, 3229-3231.	0.7	27
46	A Novel Convenient Synthesis of Benzoquinazolines. Organic Letters, 2006, 8, 255-256.	2.4	22
47	A new access to quinazolines from simple anilines. Tetrahedron, 2006, 62, 12351-12356.	1.0	21